Computational approaches to advance personalized medicine
Peter Bram 't Hoen's research group develops computational approaches that exploit molecular –omics data in combination with clinical data to better understand disease mechanisms and to advance patient diagnosis and stratification for therapeutic and life style interventions.
Jo Zhou's group aims to establish disease models using patient material and model organisms to identify regulatory networks and disease mechanisms in developmental disorders. Using genomics technology, we map the genome-wide atlas of disease-associated regulatory elements beyond the coding regions.
Engineered proteins for drug delivery
Wouter Verdurmen’s research group focuses on designing and investigating engineered proteins that overcome delivery barriers, employing synthetic binding proteins for target recognition. Various (super-resolution) microscopy techniques as well as microfluidic tumor-on-a-chip approaches are used.
Genomic technologies & immuno-genomics
Alexander Hoischen's group focuses on the application of latest genomic technologies to understand human disease. A particular emphasis is put in the understanding of genetic defects that explain immune diseases, in particular primary immunodeficiencies (PIDs).
Magnesium in health and disease
Jeroen de Baaij's research group examines the role of magnesium in health and disease. His team studies the regulation of magnesium handling by the intestine and the kidney, as well as the role of magnesium in disease including diabetes mellitus type 2 and chronic kidney disease.
Polycystic liver disease
Joost Drenth's group aims to discover novel paradigms for effective treatment of patients. Our strategy starts with disease gene discovery followed by functional studies to understand cellular pathogenesis. The main focus is polycystic liver disease, a rare inherited liver disorder.
Sander Leeuwenburgh's research group focuses on developing advanced tissue regenerative therapies, utilizing biomaterials either or not combined with biological components. These therapies exploit biomaterial properties, patient-derived cells or therapeutic molecules to empower their functionality.
Renal electrolyte handling
René Bindels' research group studies the regulation of ion transport processes in kidney and small intestine in health and disease. Current projects involve the molecular mechanisms underlying rare tubulopathies and the regulation of the newly identified calcium, magnesium and sodium transporters.
Roland Brock’s group focuses on the targeted delivery of molecules such as oligonucleotides, toxins and photosensitizers to modulate cell function and/or induce cell death. This research involves fundamental studies of formulation strategies and uptake mechanisms as well as preclinical applications.
Carl Figdor's research group tries to develop novel prognostic and predictive biomarkers, by studying tumor and blood samples from patients treated with dendritic cell (DC) vaccines. An in vitro 3D-Skin model was built to systematically study tumor- microenvironment interactions.
William Leenders' group performs targeted quantitative next generation sequencing of RNA from surgery-derived cancer tissues in retrospective studies, tries to translate the findings into personalized precision therapy with available cancer treatments, and develops innovative targeted nanomedicines.
Joost Hoenderop's group focuses on tubular transport of calcium, magnesium and sodium by the kidney tubule and the changes therein. For acquired renal disorders, uncovering the underlying mechanism, prevention and rational treatments for drug-induced toxicities is a main focus.